A metabolic drug meets its goal against heavy drinking in mid-stage trial

Altimmune's pemvidutide cut heavy drinking days in a phase 2 alcohol use disorder study, hinting at a broader use for GLP-1 drugs.

On July 28, 2026, Altimmune reported results from its phase 2 Reclaim study of pemvidutide, an injected drug that targets both the GLP-1 and glucagon receptors, in patients with alcohol use disorder. Over 24 weeks, patients on the drug averaged 4.2 fewer heavy drinking days per week versus their baseline, compared with a 2.75-day reduction for placebo. The trial met its primary endpoint with statistical significance.

Beyond self-reported drinking, a blood marker of alcohol intake (serum phosphatidylethanol) dropped 38% among treated patients while rising 5.9% in the placebo group. More treated patients fell two levels on the WHO Risk Drinking scale and logged more abstinent days. Side effects were mostly gastrointestinal — vomiting, constipation, fatigue and worsening hemorrhoids drove five patients off the drug, versus none on placebo.

The metabolic drug class is already cheap to manufacture and widely produced. If GLP-1 medicines can also treat addiction, the same industrial base could reach a large, poorly served disease burden without new manufacturing. Eli Lilly is running two 1,100-patient phase 3 AUD trials of its own dual-receptor candidate, a sign the field is moving.

These are phase 2, not confirmatory, results; the 'unequivocal' framing came from William Blair analysts, not a head-to-head trial. Altimmune held $535 million in cash as of April 30 but analysts expect it will need more capital for a pivotal AUD program. The company plans to meet the FDA and to start a separate phase 3 in liver disease later in 2026.

Source: Fierce Biotech